Tom Houben

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2605678/publications.pdf Version: 2024-02-01



TOM HOUREN

#	Article	IF	CITATIONS
1	The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management. Cells, 2020, 9, 1679.	1.8	197
2	Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids. Journal of Lipid Research, 2017, 58, 1399-1416.	2.0	94
3	Inflammatory Bowel Disease: A Stressed "Gut/Feeling― Cells, 2019, 8, 659.	1.8	61
4	Bone marrowâ€specific caspaseâ€1/11 deficiency inhibits atherosclerosis development in <i>Ldlr</i> ^{<i>â^'/â^'</i>} mice. FEBS Journal, 2015, 282, 2327-2338.	2.2	60
5	Cathepsin D regulates lipid metabolism in murine steatohepatitis. Scientific Reports, 2017, 7, 3494.	1.6	47
6	The immunity–diet–microbiota axis in the development of metabolic syndrome. Current Opinion in Lipidology, 2015, 26, 73-81.	1.2	41
7	Plasma Cathepsin D Levels: A Novel Tool to Predict Pediatric Hepatic Inflammation. American Journal of Gastroenterology, 2015, 110, 462-470.	0.2	40
8	Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention. Scientific Reports, 2016, 6, 38278.	1.6	35
9	Hematopoietic overexpression of Cyp27a1 reduces hepatic inflammation independently of 27-hydroxycholesterol levels in Ldlrâ^'/â^' mice. Journal of Hepatology, 2015, 62, 430-436.	1.8	25
10	Prevention of oxLDL uptake leads to decreased atherosclerosis in hematopoietic NPC1-deficient Ldlrâ^'/â^' mice. Atherosclerosis, 2016, 255, 59-65.	0.4	25
11	Blood-derived macrophages prone to accumulate lysosomal lipids trigger oxLDL-dependent murine hepatic inflammation. Scientific Reports, 2017, 7, 12550.	1.6	25
12	Weekly Treatment of 2-Hydroxypropyl-Î ² -cyclodextrin Improves Intracellular Cholesterol Levels in LDL Receptor Knockout Mice. International Journal of Molecular Sciences, 2015, 16, 21056-21069.	1.8	17
13	MSP is a negative regulator of inflammation and lipogenesis in ex vivo models of non-alcoholic steatohepatitis. Experimental and Molecular Medicine, 2016, 48, e258-e258.	3.2	17
14	Inhibiting Extracellular Cathepsin D Reduces Hepatic Steatosis in Sprague–Dawley Rats. Biomolecules, 2019, 9, 171.	1.8	17
15	Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans. Diabetologia, 2020, 63, 374-384.	2.9	15
16	Plasma Cathepsin D Activity Rather Than Levels Correlates With Metabolic Parameters of Type 2 Diabetes in Male Individuals. Frontiers in Endocrinology, 2020, 11, 575070.	1.5	15
17	Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice. Frontiers in Immunology, 2021, 12, 675535.	2.2	13
18	Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model. PLoS ONE, 2016, 11, e0163843.	1.1	13

Tom Houben

#	Article	IF	CITATIONS
19	Cysteamine Decreases Lowâ€Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Lowâ€Density Lipoprotein Receptor–Deficient Mice. Journal of the American Heart Association, 2021, 10, e017524.	1.6	11
20	Sexâ€opposed inflammatory effects of 27â€hydroxycholesterol are mediated via differences in estrogen signaling. Journal of Pathology, 2020, 251, 429-439.	2.1	9
21	Pneumococcal Immunization Reduces Neurological and Hepatic Symptoms in a Mouse Model for Niemann-Pick Type C1 Disease. Frontiers in Immunology, 2018, 9, 3089.	2.2	8
22	Pro-Inflammatory Implications of 2-Hydroxypropyl-β-cyclodextrin Treatment. Frontiers in Immunology, 2021, 12, 716357.	2.2	8
23	Myosteatosis in NAFLD patients correlates with plasma Cathepsin D. Biomolecular Concepts, 2021, 12, 27-35.	1.0	7
24	Deletion of haematopoietic Dectin-2 or CARD9 does not protect from atherosclerosis development under hyperglycaemic conditions. Diabetes and Vascular Disease Research, 2020, 17, 147916411989214.	0.9	6
25	Nonalcoholic Fatty Liver Disease. Handbook of Experimental Pharmacology, 2020, , 1.	0.9	6
26	Glial contribution to cyclodextrin-mediated reversal of cholesterol accumulation in murine NPC1-deficient neurons in vivo. Neurobiology of Disease, 2021, 158, 105469.	2.1	6
27	Plasma IL-1 receptor antagonist levels correlate with the development of non-alcoholic steatohepatitis. Biomarkers in Medicine, 2015, 9, 1301-1309.	0.6	5
28	Exogenously Added Oxyphytosterols Do Not Affect Macrophageâ€Mediated Inflammatory Responses. Lipids, 2018, 53, 457-462.	0.7	5
29	Dietary plant stanol ester supplementation reduces peripheral symptoms in a mouse model of Niemann-Pick type C1 disease. Journal of Lipid Research, 2020, 61, 830-839.	2.0	5
30	OxLDL as an Inducer of a Metabolic Shift in Cancer Cells. Journal of Cancer, 2021, 12, 5817-5824.	1.2	5
31	Comment on Tauriainen et al.: Serum, liver and bile sitosterol and sitostanol in obese patients with and without NAFLD. Bioscience Reports, 2018, 38, .	1.1	4
32	The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial. Antioxidants, 2021, 10, 129.	2.2	4
33	Myeloid DLL4 Does Not Contribute to the Pathogenesis of Non-Alcoholic Steatohepatitis in Ldlr-/- Mice. PLoS ONE, 2016, 11, e0167199.	1.1	3
34	Hematopoietic Npc1 mutation shifts gut microbiota composition in Ldlrâ^'/â^' mice on a high-fat, high-cholesterol diet. Scientific Reports, 2019, 9, 14956.	1.6	3
35	Anti-Inflammatory Effects of Dietary Plant Stanol Supplementation Are Largely Dependent on the Intake of Cholesterol in a Mouse Model of Metabolic Inflammation. Biomedicines, 2021, 9, 518.	1.4	3
36	Insulin resistance is positively associated with plasma cathepsin D activity in NAFLD patients. Biomolecular Concepts, 2021, 12, 110-115.	1.0	2

#	Article	IF	CITATIONS
37	Elevated granulocyte-colony stimulating factor and hematopoietic stem cell mobilization in Niemann-Pick type C1 disease. Journal of Lipid Research, 2022, 63, 100167.	2.0	1